Castle Biosciences Inc. (CSTL) is a renowned commercial-stage dermatological cancer company headquartered in Friendswood, Texas, USA. The company began its operations in 2007 and since then has dedicated its services to developing and commercializing diagnostic and prognostic tests designed to provide physicians and their patients with more accurate and actionable information to guide treatment decisions.
The core philosophy of Castle Biosciences centers around improving health outcomes through more accurate diagnoses. They harness innovations in genomics to create diagnostic tests that, they believe, take the guesswork out of identifying potentially deadly conditions, like uveal (eye) and cutaneous (skin) melanoma, at their earliest and most treatable stages.
Their portfolio of tests prominently features DecisionDx®-Melanoma, a gene expression profile (GEP) test for use in patients diagnosed with melanoma, and DecisionDx®-UM, a GEP test for use in patients diagnosed with uveal melanoma. Both of these tests are designed to predict individual risk of metastasis. Castle Biosciences holds an extensive patent portfolio for its proprietary tests and has been commended for its meticulous research and development process.
Besides cutaneous melanoma and uveal melanoma, the company also offers a prognosis test for cutaneous squamous cell carcinoma, and another that can help to identify the risk of the recurrence of skin cancer. This multifaceted approach towards dermatological cancers showcases the company's commitment to pioneering new ways to combat and manage these diseases.
Despite their focus on dermatological cancers, Castle Biosciences is always on the lookout for opportunities to expand its suite of diagnostic solutions. They are committed to improving the lives of patients across a wide spectrum of cancers and diseases, and it is this patient-centric mindset that informs their continual research and development efforts.
As a publicly-traded company listed on the NASDAQ, Castle Biosciences has become a trusted name in the healthcare industry. The company's steady growth and resilient business model emphasizes their vision to bring the power of genomics to bear on challenging diagnostic problems. It is a leading force in innovative healthcare solutions, enabling patients and physicians to make informed treatment decisions and redefine the trajectory of cancer care outcomes around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Castle Biosciences (CSTL) has shown mixed returns recently, with a slight daily drop but strong weekly and monthly gains. The stock is considered 18% undervalued based on test volumes, reimbursement decisions, and cash reserves, despite its P/S ratio being higher than the industry average. Key risks include unresolved Medicare coverage for DecisionDx SCC and pressure on gross margins from newer tests.
This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL) using AI models to inform risk allocation. Key findings indicate strong near- and mid-term sentiment but a weak long-term outlook, with no resistance levels above the current price suggesting upside potential. The analysis provides specific position, momentum breakout, and risk hedging trading strategies tailored to different risk profiles.
Mizuho has initiated coverage on Castle Biosciences (NASDAQ:CSTL) with an "outperform" rating and a $60 price target, suggesting a significant upside. The company has a consensus "Moderate Buy" rating from analysts and recently surpassed quarterly earnings and revenue expectations. Despite positive analyst sentiment, insiders have sold a notable amount of stock in the last 90 days.
Castle Biosciences (CSTL) is scheduled to release its Q3 2026 earnings on Thursday, November 5th, with analysts predicting a loss of $0.3544 per share on revenue of $92.41 million. The company previously surpassed expectations in Q2 2026, reporting a smaller loss and higher revenue than anticipated. Despite a "Moderate Buy" consensus rating and a $42.00 average price target, company insiders have sold approximately $6.98 million worth of stock in the last 90 days.
Castle Biosciences (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the company's stock, valued at approximately $108,767, reducing his holdings by 6.75%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, CSTL shares rose 6.3% on Wednesday, and the company recently reported quarterly results that beat analyst expectations.
Castle Biosciences presented new data on its TissueCypher Barrett's Esophagus test, highlighting its potential to influence real-world care pathways by guiding endoscopy timing and endoscopic eradication therapy use. This data supports the company's push into gastrointestinal diagnostics, a key growth area, and could impact payer coverage decisions and guideline references, influencing analyst revenue and earnings forecasts. The investment narrative hinges on successful reimbursement outcomes and broader payer coverage for its molecular tests.